LLNL and BridgeBio Announce Trials for Supercomputing-Discovered Cancer Drug

June 6, 2024

June 6, 2024 — In a substantial milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory (LLNL) and BridgeBio Oncology Therapeutics (BridgeBio) today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer.

This image depicts a surface representation of the interaction among the cancer drug candidate, BBO-8520 (yellow), the natural substrate guanosine triphosphate (or GTP, orange) and a KRAS protein (cyan). Image by LLNL team.

The development of the new drug — BBO-8520 — is the result of collaboration among LLNL, BridgeBio and the National Cancer Institute (NCI)’s RAS Initiative at the Frederick National Laboratory for Cancer Research (FNL). In a first for a Department of Energy (DOE) national laboratory, the drug was discovered through DOE’s leadership in high performance computing (HPC) for mission applications, combined with an LLNL-developed platform integrating artificial intelligence (AI) and traditional physics-based drug discovery, and effective partnership with the FNL and NCI.

The drug candidate has shown promise in laboratory testing for inhibiting mutations of KRAS proteins linked to about 30% of all cancers — targets long considered “undruggable” by cancer researchers. The achievement provides hope for broad impact on cancer patients whose tumors harbor susceptible KRAS mutations. This indicates that a computational/AI drug design approach could unlock new insights into the disease and the future of cancer treatment.

“For the DOE complex, this is the first true example that high performance computing can accelerate drug discovery, which is reinforced by making it to human trials,” said LLNL Biochemical and Biophysical Systems Group Leader Felice Lightstone, principal investigator for the project. “Passing FDA clearance to get to human trials already says that the FDA has looked at the design, and we’ve met all the criteria to have a real-world application. Not only that, but we’re taking our basic research in high performance computing and converting it to an application that industry can find useful — this is a true milestone.”

After just three years of development, thanks to a legacy of scientific expertise in small-molecule research, LLNL’s unparalleled HPC capabilities and the Livermore Computer-Aided Drug Discovery (LCADD) platform, the U.S. Food and Drug Administration (FDA) cleared BBO-8520 for human trials in December 2023. The trial will focus on patients with KRASG12C mutant non-small cell lung cancer and will test the novel inhibitor for safety and efficacy.

The milestone leverages computational drug design capabilities originally motivated by a longstanding DOE-NCI partnership under the Cancer Moonshot, which aims to apply world-class computing resources at LLNL and other DOE national laboratories to advance cancer research and treatment for the public good.

Researchers on the project said the partnership’s success in developing a tangible drug candidate underscores the value of uniting expertise from the DOE national laboratories, biomedical research institutions and innovative companies to solve difficult challenges such as cancer. It also indicates the computational approach could save millions of dollars and valuable time — perhaps years — over the traditional drug discovery process, where even promising compounds can fail before reaching human testing.

“Through our collaboration with LLNL and FNL, we’ve reached a significant achievement in drug discovery for inhibiting KRAS mutations that lead to cancer,” said BridgeBio Oncology Therapeutics Chief Science Officer Pedro Beltran. “The development of BBO-8520 could only have been possible through our partnership approach and exemplifies the power of teamwork and innovation. This drug was able to reach human trials in record time and epitomizes the potential of computational and AI-enabled drug design to save time, money and lab resources on new drug discovery. It’s a testament to the bright future of our collaboration and the hope it can bring to patients in need. We are proud to continue working alongside LLNL and FNL to push the boundaries of what’s possible in cancer research.”

In addition to advancing cancer research, LLNL representatives said the milestone is validation that integrating supercomputing with AI- and physics-based computational platforms has the potential to further accelerate small-molecule drug discovery and equip DOE, the National Nuclear Security Administration and LLNL with the ability to quickly and routinely develop medical countermeasures for disease or future pandemics, aligning with broader mission focus areas in biosecurity, bio-resilience and national security.

“Through this pioneering partnership, LLNL, the Frederick National Laboratory for Cancer Research and BridgeBio have unlocked a beacon of optimism in the fight against cancer — and this is only the beginning of what we hope will be a long and fruitful collaboration,” said Pat Falcone, deputy director for science and technology at LLNL. “This rapid journey from computational simulations to human trials for this drug reflects the transformative power of research at the DOE national laboratories and ensures we are better-prepared for the next pandemic. This collaboration stands as a testament to the potential of public-private partnerships, and we invite other institutions and companies to join us in the pursuit of innovative solutions through computational and AI-aided drug design. Together, we have accelerated the pace of discovery.”

Initial research and funding for the work came from the RAS Initiative, established by NCI to explore novel approaches to attack proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers. Among all forms of RAS proteins, KRAS is the most desired target for therapeutic treatment because of the prevalence of mutant (oncogenic) KRAS in pancreatic, lung and colorectal cancer, researchers said. Mutations of the RAS family of genes are implicated in 20-30 percent of all cancers — including 95% of pancreatic cancers and 45% of colorectal cancers.

“The Frederick National Laboratory’s longstanding relationships with our colleagues at Lawrence Livermore through the NCI-DOE collaboration set the stage for this public-private partnership with BridgeBio, which represents a distinct model for drug development that encompasses world-class computing capabilities,” said Dwight Nissley, cancer biologist and head of the RAS Initiative team at FNL. “By leveraging each partner’s unique strengths, we realized a long-standing goal of the NCI, to develop novel therapeutic options for RAS-driven cancers.”

Normally, RAS proteins receive and follow signals to switch between active and inactive states. Like a light switch, mutated RAS proteins such as KRASG12C can become stuck in an ”always-on” state that causes cells to grow out of control; forming tumors and the cancer itself to spread to other parts of the body. While existing drug treatments aim to turn this switch off, cancerous cells sometimes still find ways to turn it back on again — making the treatments less effective over time. Unlike most current KRASG12C drugs, BBO-8520 targets KRASG12C in both its active and inactive states, effectively blocking its function and hindering cancer progression. This dual mechanism is believed to offer advantages over existing therapies by addressing some mechanisms of resistance that can develop over time.

Preclinical studies demonstrated promising results for BBO-8520, showing statistically significant inhibition of tumor growth in various cancer models, even in cases where resistance has emerged against other medications targeting the same protein. By binding only to the “off” conformation, existing treatments “result in a patient developing resistance quite quickly,” resulting in cancer progression, said Anna Maciag, a cancer biochemist who led the FNL’s preclinical work on BBO-8520. “This dual inhibitor hits the ‘on’ and ‘off’ states simultaneously, providing 100% coverage of the target,” Maciag added.

The studies suggest that BBO-8520 has the potential to be more effective in treating certain types of cancer, particularly those driven by mutations in the KRASG12C gene, which plays a critical role in cancer cell growth and proliferation and, for decades, has been considered undruggable by the scientific community.

While a typical drug-discovery program synthesizes many thousands of promising compounds to design and develop a drug, the team behind this research initially synthesized only a few hundred compounds to discover BBO-8520 — using the AI- and physics-based LCADD platform to narrow down the number of possible successful small molecules for synthesis. With thousands of compounds modeled in silico, the team synthesized about 850 compounds for the entire project.

The joint effort stems from Cooperative Research and Development Agreements (CRADAs) between LLNL and BridgeBio Oncology Therapeutics and between BridgeBio and FNL, aimed at advancing discovery of novel RAS inhibitors for the treatment of cancer. The CRADAs brought the three institutions together to tackle the most challenging aspects of cancer therapy: the long timeframe to bring a drug to market and the high rate of failure for promising drug candidates. LLNL also saw the problem as an important use case for advanced computing. In the coming years, LLNL and BridgeBio will continue to seek new compounds for other targets identified by the RAS Initiative, experimentally testing and validating these compounds, analyzing interactions between compounds and targets and optimizing existing compounds.

“This is a prime example of a truly collaborative spirit with a shared vision: to develop innovative therapies that target RAS-driven cancers with precision and efficacy to give new hope to cancer patients,” said LLNL’s Yue Yang, a computational chemist and a lead researcher on the project. “We want to thank BridgeBio for trusting us to become part of their team and to have an impact on future candidates as well as their ongoing drug-discovery efforts. BridgeBio’s willingness to integrate us with their plans was key to the success of this drug.”

Yang added that the LCADD platform used to discover BBO-8520 is broad and customizable to a wide range of ailments, including other forms of cancer and infectious disease. By collaborating with U.S. industry, scientists could test and improve the platform to combat future biological threats with the assurance of a validated system.

LLNL Innovation and Partnerships Office (IPO) Business Development Executive Yash Vaishnav negotiated the CRADA with BridgeBio subsidiary Theras, as well as the license agreement for the drug candidate with BridgeBio Oncology Therapeutics. Vaishnav also manages the intellectual property portfolio of KRAS inhibitors developed under the CRADA and the relationship with his counterparts at BridgeBio. IPO is the focal point for LLNL’s engagement with industry and aims to accelerate U.S. competitiveness by identifying new economic opportunities and solutions and transferring those to the private sector through licensing or partnerships.

Source: LLNL

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industry updates delivered to you every week!

HPE and NVIDIA Join Forces and Plan Conquest of Enterprise AI Frontier

June 20, 2024

The HPE Discover 2024 conference is currently in full swing, and the keynote address from Hewlett-Packard Enterprise (HPE) CEO Antonio Neri on Tuesday, June 18, was an unforgettable event. Other than being the first busi Read more…

Slide Shows Samsung May be Developing a RISC-V CPU for In-memory AI Chip

June 19, 2024

Samsung may have unintentionally revealed its intent to develop a RISC-V CPU, which a presentation slide showed may be used in an AI chip. The company plans to release an AI accelerator with heavy in-memory processing, b Read more…

ASC24 Student Cluster Competition: Who Won and Why?

June 18, 2024

As is our tradition, we’re going to take a detailed look back at the recently concluded the ASC24 Student Cluster Competition (Asia Supercomputer Community) to see not only who won the various awards, but to figure out Read more…

Qubits 2024: D-Wave’s Steady March to Quantum Success

June 18, 2024

In his opening keynote at D-Wave’s annual Qubits 2024 user meeting, being held in Boston, yesterday and today, CEO Alan Baratz again made the compelling pitch that D-Wave’s brand of analog quantum computing (quantum Read more…

Apple Using Google Cloud Infrastructure to Train and Serve AI

June 18, 2024

Apple has built a new AI infrastructure to deliver AI features introduced in its devices and is utilizing resources available in Google's cloud infrastructure.  Apple's new AI backend includes: A homegrown foun Read more…

Argonne’s Rick Stevens on Energy, AI, and a New Kind of Science

June 17, 2024

The world is currently experiencing two of the largest societal upheavals since the beginning of the Industrial Revolution. One is the rapid improvement and implementation of artificial intelligence (AI) tools, while the Read more…

HPE and NVIDIA Join Forces and Plan Conquest of Enterprise AI Frontier

June 20, 2024

The HPE Discover 2024 conference is currently in full swing, and the keynote address from Hewlett-Packard Enterprise (HPE) CEO Antonio Neri on Tuesday, June 18, Read more…

Slide Shows Samsung May be Developing a RISC-V CPU for In-memory AI Chip

June 19, 2024

Samsung may have unintentionally revealed its intent to develop a RISC-V CPU, which a presentation slide showed may be used in an AI chip. The company plans to Read more…

Qubits 2024: D-Wave’s Steady March to Quantum Success

June 18, 2024

In his opening keynote at D-Wave’s annual Qubits 2024 user meeting, being held in Boston, yesterday and today, CEO Alan Baratz again made the compelling pitch Read more…


Argonne’s Rick Stevens on Energy, AI, and a New Kind of Science

June 17, 2024

The world is currently experiencing two of the largest societal upheavals since the beginning of the Industrial Revolution. One is the rapid improvement and imp Read more…

Under The Wire: Nearly HPC News (June 13, 2024)

June 13, 2024

As managing editor of the major global HPC news source, the term "news fire hose" is often mentioned. The analogy is quite correct. In any given week, there are Read more…

Labs Keep Supercomputers Alive for Ten Years as Vendors Pull Support Early

June 12, 2024

Laboratories are running supercomputers for much longer, beyond the typical lifespan, as vendors prematurely deprecate the hardware and stop providing support. Read more…

MLPerf Training 4.0 – Nvidia Still King; Power and LLM Fine Tuning Added

June 12, 2024

There are really two stories packaged in the most recent MLPerf  Training 4.0 results, released today. The first, of course, is the results. Nvidia (currently Read more…

Highlights from GlobusWorld 2024: The Conference for Reimagining Research IT

June 11, 2024

The Globus user conference, now in its 22nd year, brought together over 180 researchers, system administrators, developers, and IT leaders from 55 top research Read more…

Atos Outlines Plans to Get Acquired, and a Path Forward

May 21, 2024

Atos – via its subsidiary Eviden – is the second major supercomputer maker outside of HPE, while others have largely dropped out. The lack of integrators and Atos' financial turmoil have the HPC market worried. If Atos goes under, HPE will be the only major option for building large-scale systems. Read more…

Comparing NVIDIA A100 and NVIDIA L40S: Which GPU is Ideal for AI and Graphics-Intensive Workloads?

October 30, 2023

With long lead times for the NVIDIA H100 and A100 GPUs, many organizations are looking at the new NVIDIA L40S GPU, which it’s a new GPU optimized for AI and g Read more…

Nvidia H100: Are 550,000 GPUs Enough for This Year?

August 17, 2023

The GPU Squeeze continues to place a premium on Nvidia H100 GPUs. In a recent Financial Times article, Nvidia reports that it expects to ship 550,000 of its lat Read more…

Everyone Except Nvidia Forms Ultra Accelerator Link (UALink) Consortium

May 30, 2024

Consider the GPU. An island of SIMD greatness that makes light work of matrix math. Originally designed to rapidly paint dots on a computer monitor, it was then Read more…

Nvidia’s New Blackwell GPU Can Train AI Models with Trillions of Parameters

March 18, 2024

Nvidia's latest and fastest GPU, codenamed Blackwell, is here and will underpin the company's AI plans this year. The chip offers performance improvements from Read more…

Choosing the Right GPU for LLM Inference and Training

December 11, 2023

Accelerating the training and inference processes of deep learning models is crucial for unleashing their true potential and NVIDIA GPUs have emerged as a game- Read more…

Synopsys Eats Ansys: Does HPC Get Indigestion?

February 8, 2024

Recently, it was announced that Synopsys is buying HPC tool developer Ansys. Started in Pittsburgh, Pa., in 1970 as Swanson Analysis Systems, Inc. (SASI) by John Swanson (and eventually renamed), Ansys serves the CAE (Computer Aided Engineering)/multiphysics engineering simulation market. Read more…

Some Reasons Why Aurora Didn’t Take First Place in the Top500 List

May 15, 2024

The makers of the Aurora supercomputer, which is housed at the Argonne National Laboratory, gave some reasons why the system didn't make the top spot on the Top Read more…

Leading Solution Providers



How AMD May Get Across the CUDA Moat

October 5, 2023

When discussing GenAI, the term "GPU" almost always enters the conversation and the topic often moves toward performance and access. Interestingly, the word "GPU" is assumed to mean "Nvidia" products. (As an aside, the popular Nvidia hardware used in GenAI are not technically... Read more…

Intel’s Next-gen Falcon Shores Coming Out in Late 2025 

April 30, 2024

It's a long wait for customers hanging on for Intel's next-generation GPU, Falcon Shores, which will be released in late 2025.  "Then we have a rich, a very Read more…

Google Announces Sixth-generation AI Chip, a TPU Called Trillium

May 17, 2024

On Tuesday May 14th, Google announced its sixth-generation TPU (tensor processing unit) called Trillium.  The chip, essentially a TPU v6, is the company's l Read more…

The NASA Black Hole Plunge

May 7, 2024

We have all thought about it. No one has done it, but now, thanks to HPC, we see what it looks like. Hold on to your feet because NASA has released videos of wh Read more…

Nvidia Shipped 3.76 Million Data-center GPUs in 2023, According to Study

June 10, 2024

Nvidia had an explosive 2023 in data-center GPU shipments, which totaled roughly 3.76 million units, according to a study conducted by semiconductor analyst fir Read more…

Q&A with Nvidia’s Chief of DGX Systems on the DGX-GB200 Rack-scale System

March 27, 2024

Pictures of Nvidia's new flagship mega-server, the DGX GB200, on the GTC show floor got favorable reactions on social media for the sheer amount of computing po Read more…

GenAI Having Major Impact on Data Culture, Survey Says

February 21, 2024

While 2023 was the year of GenAI, the adoption rates for GenAI did not match expectations. Most organizations are continuing to invest in GenAI but are yet to Read more…

AMD Clears Up Messy GPU Roadmap, Upgrades Chips Annually

June 3, 2024

In the world of AI, there's a desperate search for an alternative to Nvidia's GPUs, and AMD is stepping up to the plate. AMD detailed its updated GPU roadmap, w Read more…

  • arrow
  • Click Here for More Headlines
  • arrow